Exelixis, GSK Deal Comes To A ‘Natural, Positive End’

GSK got what it came for, Exelixis’ CEO tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet